Detalhe da pesquisa
1.
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Ann Oncol
; 27(7): 1311-6, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091807
2.
[Not Available]. / Implication de la molécule X dans la récidive du cancer de prostate (CaP) localisé.
Prog Urol
; 25(13): 727, 2015 Nov.
Artigo
em Francês
| MEDLINE | ID: mdl-26544219
3.
Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
J Pathol
; 216(4): 460-70, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18825689
4.
[Not Available]. / Méthode standardisée d'évaluation de l'infiltrat inflammatoire des carcinomes urothéliaux de vessie : reconnaissance tissulaire et comptage automatique.
Prog Urol
; 24(13): 847-8, 2014 Nov.
Artigo
em Francês
| MEDLINE | ID: mdl-26461668
5.
[Not Available]. / L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.
Prog Urol
; 24(13): 806, 2014 Nov.
Artigo
em Francês
| MEDLINE | ID: mdl-26461580
6.
Influence and optimisation of operating parameters with a new binder in wet granulation. I: use in powder form.
Eur J Pharm Biopharm
; 46(1): 95-103, 1998 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-9700027
7.
T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.
J Urol
; 166(6): 2142-7, 2001 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-11696723